February 25, 2019 05:29 AM ESTUpdated 07:57 AM

Biotech M&A is back. Ipsen set to fork out up to $1.3B for rare disease specialist Clementia

Natalie Grover

Reporter

Merger Monday is back in full swing. Along with Roche buying Spark Therapeutics $ONCE, Parisian biotech Ipsen (Euronext: $IPN) is beefing up its rare …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Biotech M&A is back. Ipsen set to fork out up to $1.3B for rare disease specialist Clementia

Natalie Grover

Reporter

Sign up to read this article for free.

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

Deputy FDA chief mulls shaking up PDUFA reauthorization structure

Updated: Novo Nordisk CEO to step down amid stock decline, timeline for successor unknown

The inside story of the six-month sprint to create the first custom CRISPR therapy for one infant’s rare disease

Lower attendance at cell and gene therapy conference mirrors challenged industry

FDA poses efficacy, safety questions over four cancer drugs ahead of two-day adcomm

Novo Nordisk’s global obesity leader is moving on; Flagship biotech gets CEO from Scholar Rock

Biotech M&A is back. Ipsen set to fork out up to $1.3B for rare dis­ease spe­cial­ist Clemen­tia

Reporter

Sign up to read this article for free.

more like this

ImmunityBio, Inc.

Remote

Biotech M&A is back. Ipsen set to fork out up to $1.3B for rare disease specialist Clementia